ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 181 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $880,000 | +10.6% | 15,489 | -14.4% | 0.05% | +14.0% |
Q2 2021 | $796,000 | -18.2% | 18,091 | -8.3% | 0.04% | -23.2% |
Q1 2021 | $973,000 | +19.4% | 19,724 | +1.8% | 0.06% | -5.1% |
Q4 2020 | $815,000 | -59.5% | 19,366 | -55.9% | 0.06% | -9.2% |
Q3 2020 | $2,010,000 | -64.2% | 43,902 | -60.7% | 0.06% | -55.2% |
Q2 2020 | $5,612,000 | -13.0% | 111,769 | -10.9% | 0.14% | -14.7% |
Q1 2020 | $6,453,000 | -24.3% | 125,472 | -9.1% | 0.17% | +41.7% |
Q4 2019 | $8,524,000 | +3757.0% | 137,980 | +3647.4% | 0.12% | +3900.0% |
Q3 2019 | $221,000 | -57.0% | 3,682 | -39.6% | 0.00% | -70.0% |
Q2 2019 | $514,000 | +18.2% | 6,095 | +33.8% | 0.01% | +11.1% |
Q1 2019 | $435,000 | +75.4% | 4,556 | +30.1% | 0.01% | +80.0% |
Q4 2018 | $248,000 | -38.0% | 3,502 | -25.1% | 0.01% | -37.5% |
Q3 2018 | $400,000 | -91.8% | 4,677 | -88.9% | 0.01% | -93.5% |
Q2 2018 | $4,869,000 | +1161.4% | 42,007 | +779.5% | 0.12% | +1027.3% |
Q1 2018 | $386,000 | – | 4,776 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |